Predictors for extremely low serum infliximab trough concentration in patients with crohn's disease

被引：0
|
作者：
Mak, Lung-Yi [1 ]
Tong, Teresa [1 ]
Chen, Equal L. J. [1 ]
Ko, Michael [1 ]
To, Elvis [1 ]
Liu, Kevin S. H. [1 ]
Hung, Ivan F. N. [1 ]
Leung, Wai K. [1 ]
机构：
[1] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2016年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1568
引用
收藏
页码：169 / 169
页数：1
相关论文
共 50 条
  • [31] Predictors of Sustained Response to Infliximab in Patients With Crohn's Disease: A Single Cohort Study
    Duricova, Dana
    Malickova, Karin
    Bortlik, Martin
    Machkova, Nadezda
    Komarek, Viktor
    Bouzkova, Eva
    Lukas, Milan
    GASTROENTEROLOGY, 2011, 140 (05) : S593 - S593
  • [32] A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease
    Levesque, B. G.
    Greenberg, G. R.
    Zou, G.
    Sandborn, W. J.
    Singh, S.
    Hauenstein, S.
    Ohrmund, L.
    Wong, C. J.
    Stitt, L. W.
    Shackelton, L. M.
    King, D.
    Lockton, S.
    Ducharme, J.
    Feagan, B. G.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (10) : 1126 - 1135
  • [33] Desensitisation to infliximab in patients with Crohn's disease
    Lelong, J
    Duburque, C
    Fournier, C
    Colombel, JF
    Desreumaux, P
    Tonnel, AB
    Wallaert, B
    REVUE DES MALADIES RESPIRATOIRES, 2005, 22 (02) : 239 - 246
  • [34] Transmural healing is associated with higher infliximab trough levels in Crohn's disease
    Albshesh, A.
    Unger, B.
    Ben Horin, S.
    Eliakim, R.
    Kopylov, U.
    Carter, D.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S454 - S454
  • [35] High Infliximab Trough Levels are Associated With Mucosal Healing in Crohn's Disease
    Van Moerkercke, Wouter
    Ackaert, Chloe
    Compernolle, Griet
    Jurgens, Matthias
    Cleynen, Isabelle
    Van Assche, Gert A.
    Rutgeerts, Paul J.
    Gils, Ann
    Vermeire, Severine
    GASTROENTEROLOGY, 2010, 138 (05) : S60 - S60
  • [36] Is there a difference in trough levels and immunogenicity between Crohn's disease and ulcerative colitis patients treated with infliximab?
    Perdigoto, D.
    Macedo, C.
    Portela, F.
    Lopes, S.
    Ferreira, M.
    Ferreira, M.
    Mendes, S.
    Tome, L.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S475 - S475
  • [37] Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn's Disease
    Orts, Beatriz
    Gutierrez, Ana
    Madero, Lucia
    Sempere, Laura
    Frances, Ruben
    Zapater, Pedro
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [38] Infliximab Drug Trough Levels Do Not Correlate With Infectious Complication Risk in Patients With Crohn's Disease
    Lee, Helen
    Schneider, Yecheskel
    Lichtenstein, Gary R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S358 - S358
  • [39] Subcutaneous Infliximab Concentration Thresholds for Mucosal and Transmural Healing in Patients With Crohn's Disease
    Hong, Sung Noh
    Song, Joo Hye
    Kim, Sung Jin
    Park, Yoon Ha
    Choi, Chang Wan
    Kim, Ji Eun
    Kim, Eun Ran
    Chang, Dong Kyung
    Kim, Young-Ho
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025, 61 (02) : 313 - 322
  • [40] Serum microRNA levels in patients with Crohn's disease during induction therapy by infliximab
    Fujioka, Shin
    Nakamichi, Ikuo
    Esaki, Motohiro
    Asano, Kouichi
    Matsumoto, Takayuki
    Kitazono, Takanari
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 (06) : 1207 - 1214
12345